PIK3CA and ovarian carcinoma: Matulonis and colleagues initially reported the combination between BKM120, a nonselective PI3K inhibitor, and olaparib in patients with breast and ovarian cancers was possible with dose attenuation of the BKM120 in 2017 as we were initiating this trial.40